Short Interest in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Decreases By 95.7%

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was the target of a large decrease in short interest in July. As of July 15th, there was short interest totaling 340,264 shares, a decrease of 95.7% from the June 30th total of 7,845,889 shares. Currently, 0.3% of the company’s stock are short sold. Based on an average trading volume of 2,998,595 shares, the days-to-cover ratio is presently 0.1 days.

Analyst Ratings Changes

A number of analysts recently weighed in on CPRX shares. Oppenheimer cut shares of Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. Wall Street Zen cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Two analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Advisory Services Network LLC bought a new position in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $39,000. Quarry LP bought a new position in Catalyst Pharmaceuticals during the 3rd quarter worth $40,000. Clearstead Advisors LLC increased its position in Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 1,167 shares during the period. Smartleaf Asset Management LLC increased its position in Catalyst Pharmaceuticals by 55.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 630 shares during the period. Finally, Larson Financial Group LLC lifted its stake in Catalyst Pharmaceuticals by 552.7% in the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,564 shares during the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Performance

CPRX remained flat at $31.49 on Friday. The company has a market cap of $3.86 billion, a P/E ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74. The stock has a 50 day moving average price of $31.39 and a two-hundred day moving average price of $27.30. Catalyst Pharmaceuticals has a 52-week low of $19.05 and a 52-week high of $32.56.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).